Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
VVOS Stock Chart & Stats
$2.02
-$0.06(-1.47%)
At close: 4:00 PM EST
$2.02
-$0.06(-1.47%)
Day’s Range― - ―
52-Week Range$1.98 - $7.95
Previous CloseN/A
Volume144.69K
Average Volume (3M)421.86K
Market Cap
$18.61M
Enterprise Value$35.89M
Total Cash (Recent Filing)$3.09M
Total Debt (Recent Filing)$4.12M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 26, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding8,988,106
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.71
Price to Sales (P/S)1.43
P/FCF Ratio-1.62
Enterprise Value/Market Cap1.93
Enterprise Value/Revenue2.07
Enterprise Value/Gross Profit3.72
Enterprise Value/Ebitda-2.25
Forecast
1Y Price Target
$6.25Price Target Upside209.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business StrategyVivos' new business strategy is focused on contractual alliances with and outright acquisitions of sleep specialty providers and sleep centers, aligning revenue generation more directly to sales of its novel appliance.
FDA ApprovalThe DNA appliance was cleared by the FDA to treat moderate and severe OSA in adults and children, making it the only oral appliance FDA cleared to treat children with OSA.
Revenue GrowthSCN integration drives sharp uptick in revenues, with Q3 FY25 revenues up 76% YoY.
Bears Say
Cash FlowAdditional financing is required as the company had $3.1 million in cash with a Q3 cash burn of $4 million, indicating imminent fundraising needs.
Financing NeedsOngoing cash burn, as well as an expressed interest in making strategic acquisitions, present the likelihood of further dilutive financing in the next few quarters.
Operating ExpensesOperating expenses have increased significantly due to SCN costs, but some expenses are transitional, suggesting potential for improved margins.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $1.98 and its highest was $7.95 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $18.61M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 100 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on Nov 19, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.51 by $0.02.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Undervalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.5.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 8,988,106 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.51. Following the earnings report the stock price went down -10.169%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
VVOS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call displayed strong revenue growth and strategic steps towards expanding market presence through the acquisition and alliance models. However, increased operational costs and net loss pose challenges. Despite these hurdles, the company is optimistic about its new business model and future revenue potential.View all VVOS earnings summariesVVOS Stock 12 Month Forecast
Average Price Target
$6.25
▲(209.41% Upside)
Technical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
0.97%
Insiders
1.11% Mutual Funds
3.80% Other Institutional Investors
90.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---